- Home
- BNTC vs MREO Comparison
BNTC vs MREO Comparison
Compare BNTC & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTC
- MREO
- Stock Information
- Founded
- BNTC 1995
- MREO 2015
- Country
- BNTC United States
- MREO United Kingdom
- Employees
- BNTC N/A
- MREO N/A
- Industry
- BNTC Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- BNTC Health Care
- MREO Health Care
- Exchange
- BNTC Nasdaq
- MREO Nasdaq
- Market Cap
- BNTC 366.6M
- MREO 438.8M
- IPO Year
- BNTC N/A
- MREO N/A
- Fundamental
- Price
- BNTC $12.89
- MREO $1.66
- Analyst Decision
- BNTC Strong Buy
- MREO Strong Buy
- Analyst Count
- BNTC 6
- MREO 5
- Target Price
- BNTC $23.83
- MREO $7.20
- AVG Volume (30 Days)
- BNTC 234.8K
- MREO 3.5M
- Earning Date
- BNTC 05-14-2025
- MREO 08-12-2025
- Dividend Yield
- BNTC N/A
- MREO N/A
- EPS Growth
- BNTC N/A
- MREO N/A
- EPS
- BNTC N/A
- MREO N/A
- Revenue
- BNTC N/A
- MREO N/A
- Revenue This Year
- BNTC N/A
- MREO N/A
- Revenue Next Year
- BNTC N/A
- MREO $52.34
- P/E Ratio
- BNTC N/A
- MREO N/A
- Revenue Growth
- BNTC N/A
- MREO N/A
- 52 Week Low
- BNTC $7.05
- MREO $1.58
- 52 Week High
- BNTC $17.15
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- BNTC 50.13
- MREO 29.70
- Support Level
- BNTC $12.57
- MREO $2.77
- Resistance Level
- BNTC $13.88
- MREO $3.05
- Average True Range (ATR)
- BNTC 1.18
- MREO 0.18
- MACD
- BNTC 0.02
- MREO -0.06
- Stochastic Oscillator
- BNTC 62.63
- MREO 9.76
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).